WASHINGTON (MarketWatch) — The Democrats on the House Committee on Oversight and Government Reform have released a memo on the documents obtained about the pricing of drugs by Valeant Pharmaceuticals . The memo shows how Valeant set drug prices — it lifted the price of Isuprel by 525% and Nitropress by 212% — and Valeant’s public-relations strategy, which was to focus on patient assistant programs. From 2014 to 2015, Valeant increased the prices of more than 20 additional “U.S. Prescription Products” by more than 200%, the document says ahead of a hearing on Thursday about pricing.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News